Compare Gilead Sciences, Inc. (GILD) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sprott Uranium Miners ETF — how do they compare? Gilead Sciences, Inc. trades at $134.79 (market cap $163.51B), while Sprott Uranium Miners ETF trades at $48.9. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Sprott Uranium Miners ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| GILD | URNM | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $83.99 |
52-Week Low | $108.22 | $44.14 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
URNM (Sprott Uranium Miners ETF) trades at $49.49, down 4.07% today amid bearish technical signals with all 15 moving averages indicating sell signals. The ETF provides concentrated exposure to uranium miners, benefiting from the nuclear energy revival driven by AI power demand. Recent news highlights uranium's strategic role in meeting data center electricity needs, though the sector experienced recent volatility with uranium stocks declining.
The uranium sector faces a decade-long supply-demand imbalance favoring miners, though URNM's pure-miner focus brings higher volatility. Key risks include uranium price fluctuations and miner operational challenges. Analyst sentiment is mixed with some seeing long-term opportunity while others caution about stretched valuations relative to underlying uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
